Covid and Johnson & Johnson JNJ earnings Q3 2021

Johnson & Johnson said it sold $502 million of its Covid-19 vaccine in the third quarter, in its earnings report on Tuesday that beat Wall Street earnings expectations.

Here’s what J&J did compared to what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted earnings per share: $2.60 per share versus $2.35 expected.
  • Revenue: $23.34 billion versus $23.72 billion forecast.

J&J shares jumped more than 1% in pre-market trading.

The J&J report has come under fire for its handling of the opioid crisis and the development of a relatively less effective Covid vaccine under outgoing CEO Alex Gorsky.

In a press release, Gorsky said financial results “demonstrate strong performance across Johnson & Johnson, driven by strong out-of-market results in pharmaceuticals, continued recovery in medical devices, and strong growth in consumer health.”

This is an evolving story. . Please check back for updates

Correction: This story has been updated to reflect that J&J missed revenue estimates.

.

Leave a Comment